Effective Management and Prevention of Neratinib-Induced Diarrhea

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Unknown venue

• Publication date

  2015-11-16

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study

  2023cited by this paper
• Efficacy and CNS progression analysis from the randomized phase 2 trial of neratinib + paclitaxel vs trastuzumab + paclitaxel as first-line treatment for HER2+ metastatic breast cancer (NEfERTT).

  2015cited by this paper
• Neratinib after adjuvant chemotherapy and trastuzumab in HER2-positive early breast cancer: Primary analysis at 2 years of a phase 3, randomized, placebo-controlled trial (ExteNET).

  2015cited by this paper
• Management of diarrhea induced by epidermal growth factor receptor tyrosine kinase inhibitors.

  2014cited by this paper
• A phase II, randomized, double blind trial of calcium aluminosilicate clay versus placebo for the prevention of diarrhea in patients with metastatic colorectal cancer treated with irinotecan

  2014cited by this paper
• Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.

  2014cited by this paper
• FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial.

  2014cited by this paper
• Guidance on the management of diarrhoea during cancer chemotherapy.

  2014cited by this paper
• TBCRC 022: Phase II trial of neratinib for patients (Pts) with human epidermal growth factor receptor 2 (HER2+) breast cancer and brain metastases (BCBM).

  2014cited by this paper
• LBA39_PRNERATINIB (N) WITH OR WITHOUT TEMSIROLIMUS (TEM) IN PATIENTS (PTS) WITH NON-SMALL CELL LUNG CANCER (NSCLC) CARRYING HER2 SOMATIC MUTATIONS: AN INTERNATIONAL RANDOMIZED PHASE II STUDY

  2014cited by this paper
• Randomized phase III trial exploring the use of long-acting release octreotide in the prevention of chemotherapy-induced diarrhea in patients with colorectal cancer: the LARCID trial.

  2014cited by this paper
• Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial.

  2014cited by this paper
• PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma.

  2014cited by this paper
• Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.

  2014cited by this paper
• A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.

  2013cited by this paper
• Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).

  2013cited by this paper
• Safety and efficacy of neratinib (HKI-272) plus vinorelbine in the treatment of patients with ErbB2-positive metastatic breast cancer pretreated with anti-HER2 therapy.

  2013cited by this paper
• A randomised phase III intergroup trial comparing high-dose infusional 5-fluorouracil with or without folinic acid with standard bolus 5-fluorouracil/folinic acid in the adjuvant treatment of stage III colon cancer: the Pan-European Trial in Adjuvant Colon Cancer 2 study.

  2013cited by this paper
• Combination neratinib (HKI-272) and paclitaxel therapy in patients with HER2-positive metastatic breast cancer

  2013cited by this paper
• 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial.

  2013cited by this paper
• Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study

  2013cited by this paper
• Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.

  2012cited by this paper
• Comprehensive analysis of kinase inhibitor selectivity

  2011cited by this paper
• Practice guidance on the management of acute and chronic gastrointestinal problems arising as a result of treatment for cancer

  2011cited by this paper
• Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer.

  2010cited by this paper
• Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

  2010cited by this paper
• Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.

  2010cited by this paper
• F1000 highlights

  2010cited by this paper
• Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: A phase I/II study.

  2009cited by this paper
• F1000 highlights

  2009cited by this paper
• A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors

  2009cited by this paper
• Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer.

  2009cited by this paper
• Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer.

  2008cited by this paper
• EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer.

  2008cited by this paper
• Lactobacillus supplementation for diarrhoea related to chemotherapy of colorectal cancer: a randomised study

  2007cited by this paper
• Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.

  2007cited by this paper
• Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea

  2007cited by this paper
• Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.

  2007cited by this paper
• Epirubicin and cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy for early breast cancer.

  2006cited by this paper
• Randomized controlled trial of reduced-dose bolus fluorouracil plus leucovorin and irinotecan or infused fluorouracil plus leucovorin and oxaliplatin in patients with previously untreated metastatic colorectal cancer: a North American Intergroup Trial.

  2006cited by this paper
• A multicenter, randomized trial of long-acting octreotide for the optimum prevention of chemotherapy-induced diarrhea: results of the STOP trial.

  2006cited by this paper
• Phase III trial of capecitabine plus oxaliplatin as adjuvant therapy for stage III colon cancer: a planned safety analysis in 1,864 patients.

  2006cited by this paper
• Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06.

  2006cited by this paper
• Estimating the cost of illness in colorectal cancer patients who were hospitalized for severe chemotherapy-induced diarrhea.

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Clinical implications of chemotherapy-induced diarrhea in patients with cancer.

  2005cited by this paper
• Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale.

  2005cited by this paper
• Capecitabine as adjuvant treatment for stage III colon cancer.

  2005cited by this paper
• Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089.

  2005cited by this paper
• Phase II study of activated charcoal to prevent irinotecan-induced diarrhea.

  2004cited by this paper
• Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer.

  2004cited by this paper
• Antitumor Activity of HKI-272, an Orally Active, Irreversible Inhibitor of the HER-2 Tyrosine Kinase

  2004cited by this paper
• Recommended guidelines for the treatment of cancer treatment-induced diarrhea.

  2004cited by this paper
• Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.

  2004cited by this paper
• Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial.

  2003cited by this paper
• Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.

  2003cited by this paper
• First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin.

  2002cited by this paper
• Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results.

  2002cited by this paper
• Prevention of irinotecan (CPT‐11)‐induced diarrhea by oral alkalization combined with control of defecation in cancer patients

  2001cited by this paper
• The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study.

  2000cited by this paper
• Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer.

  2000cited by this paper
• Management of cancer treatment-related diarrhea. Issues and therapeutic strategies.

  2000cited by this paper
• Octreotide does not prevent diarrhea in patients treated with weekly 5-fluorouracil plus high-dose leucovorin.

  1998cited by this paper
• Recommended guidelines for the treatment of chemotherapy-induced diarrhea.

  1998cited by this paper
• Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.

  1998cited by this paper
• Subcutaneous octreotide versus oral loperamide in the treatment of diarrhea following chemotherapy

  1993cited by this paper

• Butyrate Modulates Intestinal Microbiome and Epithelial Function to Attenuate Irinotecan-induced GI Toxicity

  2025cites this paper
• Final findings from the CONTROL trial: Strategies to reduce the incidence and severity of neratinib-associated diarrhea in patients with HER2-positive early-stage breast cancer

  2022cites this paper
• Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends

  2022cites this paper
• Pertuzumab is a humanized recombinant anti-HER2 mon- oclonal antibody that inhibits dimerization of HER2 with other HER family receptors and is synergistic with trastu-

  2021cites this paper
• DDDT_A_281599 2711..2720

  2021cites this paper
• The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer

  2021cites this paper
• Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: diarrheal toxicity in the CONTROL trial.

  2020cites this paper
• Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

  2020cites this paper
• Pharmacokinetics and safety of neratinib during co-administration with loperamide in healthy subjects

  2019cites this paper
• Neratinib in Early-Stage Breast Cancer: A Profile of Its Use in the EU

  2019cites this paper
• Neratinib in Combination With Trastuzumab for the Treatment of Patients With Advanced HER2‐positive Breast Cancer: A Phase I/II Study

  2019cites this paper
• The characterization, management, and future considerations for ErbB-family TKI-associated diarrhea

  2019cites this paper
• Patterns of occurrence and implications of neratinib-associated diarrhea in patients with HER2-positive breast cancer: analyses from the randomized phase III ExteNET trial

  2019cites this paper
• Safety and Efficacy Profile of Neratinib: A Systematic Review and Meta-Analysis of 23 Prospective Clinical Trials

  2018cites this paper
• Neratinib for the treatment of HER2-positive early stage breast cancer

  2017cites this paper
• Advances in the management of HER2-positive early breast cancer.

  2017cites this paper
• Pharmacokinetics of neratinib during coadministration with lansoprazole in healthy subjects

  2017cites this paper
• HER2-positive breast cancer: is more treatment better?

  2016cites this paper
• Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations

  2016cites this paper
• Neratinib in HER-2-positive breast cancer: results to date and clinical usefulness

  2016cites this paper
• Improved tolerability of neratinib in patients with HER2-positive Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: The CONTROL trial early-stage breast cancer: The CONTROL trial

  year unknowncites this paper